There was a significantly (p < 0.05) greater incidence of cardiovascular/ thromboembolic events (myocardial infarction, ischemia, cerebrovascular accident, deep vein thrombosis and pulmonary embolism) detected in the parecoxib/ valdecoxib treatment group compared to the placebo/ placebo treatment group for the IV dosing period (2.2% and 0.0% respectively) and over the entire study period (4.8% and 1.3% respectively).